{"doi":"10.1016/j.bbi.2025.106086","title":"Colonoscopic fecal microbiota transplantation for Mild-to-Moderate Parkinson’s Disease: A randomized controlled trial","abstract":null,"journal":"Brain, Behavior, and Immunity","year":2025,"id":645184,"datarank":0.42498200160843247,"base_score":2.833213344056216,"endowment":2.833213344056216,"self_citation_contribution":0.42498200160843247,"citation_network_contribution":0.0,"self_endowment_contribution":0.42498200160843247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1679813,"name":"Liujun Xue","orcid":null,"position":1,"is_corresponding":false},{"id":1679814,"name":"Minna Zhang","orcid":null,"position":2,"is_corresponding":false},{"id":265910,"name":"Peng Shen","orcid":"0000-0002-5689-1098","position":3,"is_corresponding":false},{"id":1679815,"name":"Wenzhuo Zhao","orcid":null,"position":4,"is_corresponding":false},{"id":334685,"name":"Qiang Tong","orcid":"0000-0003-1016-1839","position":5,"is_corresponding":false},{"id":1679816,"name":"Shangnong Wu","orcid":null,"position":6,"is_corresponding":false},{"id":1679817,"name":"Weijie Dai","orcid":null,"position":7,"is_corresponding":false},{"id":1224625,"name":"Xiaozhong Yang","orcid":null,"position":8,"is_corresponding":false},{"id":1337156,"name":"Honggang Wang","orcid":"0000-0001-7582-9102","position":9,"is_corresponding":false},{"id":1479437,"name":"Jingyi Wang","orcid":"0000-0001-6934-5654","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Colonoscopic fecal microbiota transplantation for Mild-to-Moderate Parkinson’s Disease: A randomized controlled trial","abstract":"OBJECTIVE: Growing evidence supports the efficacy and safety of fecal microbiota transplantation (FMT) in treating Parkinson's disease (PD). Fecal microbiota are commonly transplanted via oral capsules, a nasojejunal tube, or colonoscopy, but freezing often decreases the diversity and viability of transplanted microbiota. This single-center, double-blind, randomized, placebo-controlled trial aims to explore the efficacy and safety of fresh FMT via colonoscopy in dealing with PD. METHODS: Thirty patients with mild-to-moderate PD (Hoehn-Yahr stage I-III) were randomly assigned into the FMT group (fresh FMT via colonoscopy) and placebo group (saline injection via colonoscopy) in a 1:1 ratio. Motor and non-motor symptoms, constipation, quality of life, cognitive function, emotional state and sleep quality were assessed using relevant scales. Fecal samples were harvested before and at 4, 8 and 12 weeks after treatment for metagenomic and metabolomics analyses. RESULTS: A total of 30 patients with mild-to-moderate PD were enrolled in the present study, involving 18 males and 12 females with a median age of 68 years, a median age of onset of 63.5 years, and a median disease duration of 3 years. At 12 weeks, scores of the UPDRS Ⅲ (group × time effect, B = - 8.80 [-13.79, -3.81]), PAC-QOL (group × time effect, B = - 29.67 [-45.35, -13.98]), UPDRS Ⅱ (group × time effect, B = - 5.07 [-8.85, -1.28]), NMSS (group × time effect, B = - 35.60 [-53.59, -17.61]), PDQ-39 (group × time effect, B = - 17.80 [-28.21, -7.39]), HAMA (group × time effect, B = - 1.66 [-2.92, -0.40]), and HAMD (group × time effect, B = - 1.33 [-2.49, -0.16]) were significantly reduced in the FMT group, while CSBM per week (group × time effect, B = 3.03 [1.42, 4.63]) and the Bristol Stool Scale score (group × time effect, B = 1.95 [0.12, 3.79]) significantly increased (all P < 0.05). Significant alterations were seen in the gut microbiota and fecal metabolites in the FMT group. No adverse events were observed during the follow-up period. CONCLUSION: Fresh FMT via colonoscopy is a safe and well-tolerated procedure for treating mild-to-moderate PD. It effectively alleviates motor and non-motor symptoms, thus facilitating defecation and improving the quality of life. These effects can be maintained for a minimum of 12 weeks and may be attributed to the optimization of gut microbiota and fecal metabolites.","is_dataset_classified":null,"base_score":2.833213344056216,"endowment":2.833213344056216,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40848995","pmcid":null,"openalex_id":"https://openalex.org/W4413440274","authors":[],"funders":[{"funder_name":"Nanjing Medical University","grant_id":"NMUB20230108","title":null}],"total_grants":1,"fwci":6.4074,"citation_percentile":0.9744572,"influential_citations":0,"citation_trend":[{"year":2025,"count":3},{"year":2026,"count":13}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.bbi.2025.106086","host_type":"journal"},{"url":"https://doi.org/10.1016/j.bbi.2025.106086","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0889159125003216?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0889159125003216?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40848995","host_type":"repository"}],"fields_of_study":["Gut microbiota and health","Clostridium difficile and Clostridium perfringens research","Gastrointestinal motility and disorders","Humans","Fecal Microbiota Transplantation","Male","Female","Middle Aged","Parkinson Disease","Aged","Double-Blind Method","Quality of Life","Colonoscopy","Feces","Treatment Outcome","Gastrointestinal Microbiome","Constipation"],"mesh_terms":["Gastrointestinal Microbiome","Fecal Microbiota Transplantation","Aged","Colonoscopy","Constipation","Double-Blind Method","Feces","Female","Humans","Male","Middle Aged","Parkinson Disease","Quality of Life","Treatment Outcome"],"keywords":["Fecal bacteriotherapy","Randomized controlled trial","Parkinson's disease","Feces","Medicine","Transplantation","Colonoscopy","Internal medicine","Disease","Gastroenterology","Biology","Antibiotics","Clostridium difficile","Microbiology","Colorectal cancer","Safety","efficacy","Parkinson’s Disease","Fecal Microbiota Transplantation","Multi-omics Analyses"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T03:24:47.420658Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}